Literature DB >> 12498394

Deregulated activation of matriptase in breast cancer cells.

Christelle M Benaud1, Michael Oberst, Robert B Dickson, Chen-Yong Lin.   

Abstract

Matriptase is an epithelial-derived, cell surface serine protease. This protease activates hepatocyte growth factor (HGF) and urokinase plasminogen activator (uPA), two proteins thought to be involved in the growth and motility of cancer cells, particularly carcinomas, and in the vascularization of tumors. Thus, matriptase may play an important role in the progression of carcinomas, such as breast cancer. We examined the regulation of activation of matriptase in human breast cancer cells, in comparison to non-transformed mammary epithelial cells 184A1N4 and MCF-10A. Results clearly indicated that unlike non-transformed mammary epithelial cells, breast cancer cells do not respond to the known activators of matriptase, serum and sphingosine 1-phosphate (S1P). Similar levels of activated matriptase were detected in breast cancer cells, grown in the presence or absence of S1P. However, up to five-fold higher levels of activated matriptase were detected in the conditioned media from the cancer cells grown in the absence of serum and S1P, when compared to non-transformed mammary epithelial cells. S1P also induces formation of cortical actin structures in non-transformed cells, but not in breast cancer cells. These results show that in non-transformed cells, S1P induces a rearrangement of the actin cytoskeleton and stimulates proteolytic activity on cell surfaces. In contrast, S1P treatment of breast cancer cells does not activate matriptase, and instead these cells constitutively activate the protease. In addition, breast cancer cells respond differently to S1P in terms of the regulation of actin cytoskeletal structures. Matriptase and its cognate inhibitor, HGF activator inhibitor 1 (HAI-1) colocalize on the cell periphery of breast cancer cells and form stable complexes in the extracellular milieu, suggesting that the inhibitor serves to prevent undesired proteolysis in these cells. Finally, we demonstrate that treatment of T-47D cells with epidermal growth factor (EGF), which promotes cell ruffling, stimulates increased accumulation of activated matriptase at the sites of membrane ruffling, suggesting a possible functional role at these sites.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12498394     DOI: 10.1023/a:1020985632550

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  44 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Isolation and characterization of alpha 2-macroglobulin-protease complexes from purified mouse mammary tumor virus and culture supernatants from virus-infected cell lines.

Authors:  L Menéndez-Arias; C Risco; S Oroszlan
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

3.  Sphingosine-1-phosphate inhibits motility of human breast cancer cells independently of cell surface receptors.

Authors:  F Wang; J R Van Brocklyn; L Edsall; V E Nava; S Spiegel
Journal:  Cancer Res       Date:  1999-12-15       Impact factor: 12.701

4.  Identification and characterization of a novel matrix-degrading protease from hormone-dependent human breast cancer cells.

Authors:  Y E Shi; J Torri; L Yieh; A Wellstein; M E Lippman; R B Dickson
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

5.  Loss of basement membrane components by invasive tumors but not by their benign counterparts.

Authors:  S H Barsky; G P Siegal; F Jannotta; L A Liotta
Journal:  Lab Invest       Date:  1983-08       Impact factor: 5.662

6.  Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model.

Authors:  G A Soff; J Sanderowitz; S Gately; E Verrusio; I Weiss; S Brem; H C Kwaan
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

7.  Rho GTPases are over-expressed in human tumors.

Authors:  G Fritz; I Just; B Kaina
Journal:  Int J Cancer       Date:  1999-05-31       Impact factor: 7.396

8.  High levels of TIMP-2 correlate with adverse prognosis in breast cancer.

Authors:  A Remacle; K McCarthy; A Noël; T Maguire; E McDermott; N O'Higgins; J M Foidart; M J Duffy
Journal:  Int J Cancer       Date:  2000-03-20       Impact factor: 7.396

9.  Expression of the metalloproteinase matrilysin in DU-145 cells increases their invasive potential in severe combined immunodeficient mice.

Authors:  W C Powell; J D Knox; M Navre; T M Grogan; J Kittelson; R B Nagle; G T Bowden
Journal:  Cancer Res       Date:  1993-01-15       Impact factor: 12.701

10.  Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells.

Authors:  R Khokha; M J Zimmer; C H Graham; P K Lala; P Waterhouse
Journal:  J Natl Cancer Inst       Date:  1992-07-01       Impact factor: 13.506

View more
  23 in total

1.  Endogenous expression of matriptase in neural progenitor cells promotes cell migration and neuron differentiation.

Authors:  Jung-Da Fang; Hsiao-Chin Chou; Hsiu-Hui Tung; Pao-Yi Huang; Sheau-Ling Lee
Journal:  J Biol Chem       Date:  2010-12-13       Impact factor: 5.157

2.  Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition.

Authors:  Jehng-Kang Wang; Ming-Shyue Lee; I-Chu Tseng; Feng-Pai Chou; Ya-Wen Chen; Amy Fulton; Herng-Sheng Lee; Cheng-Jueng Chen; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2009-06-17       Impact factor: 4.249

Review 3.  Matriptase: potent proteolysis on the cell surface.

Authors:  Karin List; Thomas H Bugge; Roman Szabo
Journal:  Mol Med       Date:  2006 Jan-Mar       Impact factor: 6.354

4.  Matriptase is inhibited by extravascular antithrombin in epithelial cells but not in most carcinoma cells.

Authors:  Feng-Pai Chou; Han Xu; Ming-Shyue Lee; Ya-Wen Chen; O X Durand Richards; Richard Swanson; Steven T Olson; Michael D Johnson; Chen-Yong Lin
Journal:  Am J Physiol Cell Physiol       Date:  2011-07-27       Impact factor: 4.249

5.  Clinical significance of TMPRSS4 in prostate cancer.

Authors:  Guohai Shi; Xiaoqun Yang; Bo Dai; Hailiang Zhang; Yijun Shen; Yao Zhu; Yiping Zhu; Wenjun Xiao; Chunguang Ma; Linguo Wen; Xiaojian Qin; Dalong Cao; Dingwei Ye
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

6.  Matriptase-3 is a novel phylogenetically preserved membrane-anchored serine protease with broad serpin reactivity.

Authors:  Roman Szabo; Sarah Netzel-Arnett; John P Hobson; Toni M Antalis; Thomas H Bugge
Journal:  Biochem J       Date:  2005-08-15       Impact factor: 3.857

7.  Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Boye Schnack Nielsen; Thomas H Bugge
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

8.  Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation.

Authors:  Karin List; Roman Szabo; Alfredo Molinolo; Virote Sriuranpong; Vivien Redeye; Tricia Murdock; Beth Burke; Boye S Nielsen; J Silvio Gutkind; Thomas H Bugge
Journal:  Genes Dev       Date:  2005-08-15       Impact factor: 11.361

9.  Crystal structures of matriptase in complex with its inhibitor hepatocyte growth factor activator inhibitor-1.

Authors:  Baoyu Zhao; Cai Yuan; Rui Li; Dan Qu; Mingdong Huang; Jacky Chi Ki Ngo
Journal:  J Biol Chem       Date:  2013-02-26       Impact factor: 5.157

10.  Matriptase activation, an early cellular response to acidosis.

Authors:  I-Chu Tseng; Han Xu; Feng-Pai Chou; Gong Li; Alexander P Vazzano; Joseph P Y Kao; Michael D Johnson; Chen-Yong Lin
Journal:  J Biol Chem       Date:  2009-11-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.